Targeted Delivery of VP1 Antigen of Foot-and-mouth Disease Virus to M Cells Enhances the Antigen-specific Systemic and Mucosal Immune Response.
- Author:
Sae Hae KIM
1
;
Ha Yan LEE
;
Yong Suk JANG
Author Information
- Publication Type:Original Article
- Keywords: Foot-and-mouth disease virus; M cell; Mucosal immunity; Systemic immunity
- MeSH: Administration, Oral; Animals; Foot-and-Mouth Disease; Foot-and-Mouth Disease Virus; Imidazoles; Immunity, Mucosal; Immunization; Immunoglobulin A; Immunoglobulin G; Lymphoid Tissue; Nitro Compounds; Phenobarbital; Vaccination
- From:Immune Network 2013;13(4):157-162
- CountryRepublic of Korea
- Language:English
- Abstract: Application of vaccine materials through oral mucosal route confers great economical advantage in animal farming industry due to much less vaccination cost compared with that of injection-based vaccination. In particular, oral administration of recombinant protein antigen against foot-and-mouth disease virus (FMDV) is an ideal strategy because it is safe from FMDV transmission during vaccine production and can induce antigen-specific immune response in mucosal compartments, where FMDV infection has been initiated, which is hardly achievable through parenteral immunization. Given that effective delivery of vaccine materials into immune inductive sites is prerequisite for effective oral mucosal vaccination, M cell-targeting strategy is crucial in successful vaccination since M cells are main gateway for luminal antigen influx into mucosal lymphoid tissue. Here, we applied previously identified M cell-targeting ligand Co1 to VP1 of FMDV in order to test the possible oral mucosal vaccination against FMDV infection. M cell-targeting ligand Co1-conjugated VP1 interacted efficiently with M cells of Peyer's patch. In addition, oral administration of ligand-conjugated VP1 enhanced the induction of VP1-specific IgG and IgA responses in systemic and mucosal compartments, respectively, in comparison with those from oral administration of VP1 alone. In addition, the enhanced VP1-specific immune response was found to be due to antigen-specific Th2-type cytokine production. Collectively, it is suggested that the M cell-targeting strategy could be applied to develop efficient oral mucosal vaccine against FMDV infection.
